ArticleAmerican journal of cancer research2026
Clinical-pathological characteristics and prognosis of elderly primary liver cancer patients.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary liver cancer (PLC) is a highly malignant disease, with an increasing incidence among the elderly population. However, there is a lack of systematic evaluation regarding its progression, recurrence, and prognostic factors. This study aims to investigate the clinicopathologic characteristics of elderly patients with PLC and to establish predictive models for overall survival and recurrence risk in this population. A retrospective analysis was conducted on 460 elderly PLC patients admitted to Longyou County People's Hospital from January 2018 to December 2019. According to pathological types, patients were classified into hepatocellular carcinoma group (HCC, n=395), intrahepatic cholangiocarcinoma group (ICC, n=49), and combined hepatocellular-cholangiocarcinoma group (CHC, n=16). Based on clinical outcomes, patients were further grouped as survivors (n=228) and non-survivors (n=232), or recurrence (n=223) and non-recurrence (n=237) groups. To validate the predictive models, 210 elderly patients with PLC from the same hospital, admitted between January 2020 and December 2020, were included as a verification cohort. Demographic and clinical data collected included age, sex, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alpha-fetoprotein (AFP), tumor number, and tumor size. Univariate analysis was performed using the chi-square (χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.